JPRN-jRCT2031210635招募中3 期
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma - MajesTEC-3
ishikawa Kazuk0 个研究点目标入组 630 人开始时间: 2022年3月2日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 630
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •- Documented multiple myeloma as defined by the criteria: a. multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria, b. measurable disease at screening as defined by any of the following:
- •1) serum M-protein level greater than or equal to (>=) 0.5 gram per deciliter (g/dL); or
- •2) urine M-protein level >=200 milligrams (mg)/24 hours; or
- •3) serum immunoglobulin free light chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
- •- Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide; a. participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory. Stable disease or progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion
- •- Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- •- Have an eastern cooperative oncology group (ECOG) performance status score of 0, 1, or 2 at screening and prior to the start of administration of study treatment
- •- Have clinical laboratory values within the specified range
排除标准
- •Exclusion Criteria:
- •- Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients. Additional exclusion criteria pertaining to specific study drugs include:
- •a. A participant is not eligible to receive daratumumab subcutaneous (SC) in combination with pomalidomide and dexamethasone (DPd) as control therapy if any of the following are present:
- •1) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide,
- •2) Disease that is considered refractory to pomalidomide per IMWG, b. A participant is not eligible to receive daratumumab SC in combination with bortezomib and dexamethasone (DVd) as control therapy if any of the following are present:
- •1) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to bortezomib,
- •2) Grade 1 peripheral neuropathy with pain or Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0,
- •3) Disease that is considered refractory to bortezomib per IMWG,
- •4) Received a strong cytochromes P450 (CYP3A4) inducer within 5 half-lives prior to randomization
- •- Received any prior B cell maturation antigen (BCMA)-directed therapy
- •- Has disease that is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody per IMWG
- •- Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within 14 days before randomization
- •- Received a live, attenuated vaccine within 4 weeks before randomization
- •- Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary amyloid light chain amyloidosis
研究者
相似试验
进行中（未招募）
1 期
A randomized phase 3 study of Teclistamab in combination withdaratumumab and lenalidomide versus a combination of daratumumab, lenalidomide and dexamethasone in new multiple myeloma patients who cannot undergo stem cell transplant as the first therapy.Multiple MyelomaEUCTR2022-000909-28-PTJanssen-Cilag International NV1,030
招募中
1 期
A randomized phase 3 study of teclistamab in combination with daratumumab and lenalidomide; talquetamab in combination with daratumumab and lenalidomide; versus a combination of daratumumab, lenalidomide and dexamethasone in new multiple myeloma patients who cannot undergo stem cell transplant as the first therapy.Multiple MyelomaEUCTR2022-000909-28-DEJanssen-Cilag International NV1,590
进行中（未招募）
1 期
A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2020-004742-11-DKJanssen-Cilag International NV578
进行中（未招募）
1 期
A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2020-004742-11-BEJanssen-Cilag International NV578
进行中（未招募）
1 期
A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Multiple MyelomaEUCTR2020-004742-11-GRJanssen-Cilag International NV578